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ABSTRACT
Chronic kidney disease (CKD) is 
a major public health problem 
throughout the world. The major out-
comes include a rapid progression, 
with development of anaemia and 
serious complications, namely throm-
boembolic and cardiovascular events. 
The pathophysiological alterations 
depend on the CKD degree, which 
will also determine the moment to 
initiate hemodialysis and recombi-
nant erythropoietin (rhEPO) thera-
pies. Thus, the cardio-renal compli-
cation might be better prevented or 
delayed if CKD patients are earlier 
identifi ed and treated for the associa-
ted anaemia, which will depend on a 
better characterization of moderate 
stages of CKD. This study aimed to 
characterization an animal of model 
of moderate CKD induced by partial 
(¾) nephrectomy, by evaluating 
hemorheological, biochemical and 
cardiovascular profi les. Blood sam-
ples from control and CKD rats were 
collected at 0, 3, 9 and 15 weeks in 
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order to evaluate: renal function, 
hemorheological parameters, iron 
metabolism, blood lipids, peripheral 
sympathetic and serotonergic sys-
tems, redox state and infl ammatory 
markers. BP, tissues trophism inde-
xes and kidney histomorphology 
were also assessed. Our data is con-
sistent with a sustained moderate de-
gree of CKD with a quickly compen-
sated modest anaemia, though 
presenting iron metabolism distur-
bances. Despite the reasonable de-
gree of functionality of the remnant 
kidney, as suggested by the anaemia 
correction and by the kidney hyper-
trophy, several important cardiovas-
cular modifi cations were developed. 
Our model presented hypertension, 
dyslipidaemia, erythropoietic distur-
bances, sympathetic activation and 
oxidative stress. This model might be 
a good tool to study the cellular/mo-
lecular mechanisms underlying mod-
erate stages of CKD and to evaluate 
the therapeutics effi cacy for preven-
tion, treatment/correction of cardio-
renal anaemia syndromes and com-
plications in early stages.
Key-words: Moderate chronic kid-
ney disease, partial nephrectomy,  rat 
model, hemorheological data, renal 
function, iron metabolism, Cardio-
vascular profi le
INTRODUCTION
Chronic kidney disease (CKD) 
has been associated with a large num-
ber of alterations, namely anaemia, 
hypertension, infl ammation, iron me-
tabolism disturbance, white blood 
cell activation, oxidative stress and 
sympathetic overactivation1-6. How-
ever, the pathophysiological altera-
tions depend on the CKD degree, 
which will also determine the mo-
ment to initiate hemodialysis and re-
combinant erythropoietin (rhEPO) 
therapies, for correction of anaemia, 
as well as its success. Therefore, car-
diovascular events, renal failure, and 
premature death can be prevented or 
delayed if earlier identifi ed and trea-
ted for CKD6.
Animal models of CKD, achieved 
by a reduction in nephron number, 
create the possibility of testing in vivo 
the mechanisms associated to renal 
dysfunction, and might be essential to 
study the complications associated to 
CKD as well as the effi cacy of thera-
peutics to prevent or delay adverse 
effects. The most common used tech-
niques include surgical resection of 
the tissue (partial nephrectomy) and 
infarction7, but there is yet limited in-
formation about its complete charac-
terization, namely for moderate CKD 
stages, which will restrict the research 
on the molecular/cellular mechanism 
underlying the cardio-renal-anaemia 
syndrome, as well as its therapeutics. 
There is some evidence that the in-
farction model in rats presents a sig-
nifi cant increase in proteinuria, hy-
pertension and glomerulosclerosis 
when compared with the model of 
simple tissue excision (with equiva-
lent reduction of renal mass)8. This 
suggests that partial nephrectomy can 
provide a better model of CKD in rat7. 
Furthermore, there is some evidence 
of a good inter-individual variability 
of uremia in this model of CKD. 
However, it is diffi cult to standardize 
it, due to the lack of consistency of 
nephron mass reduction, and, thus, to 
reach the desired degree of uremia. 
Without a consistent characterization 
BSPHM 25-2_2ª PROVA.indd   10 23-06-2010   15:11:53
Boletim da SPHM Vol. 25 (2) Abril, Maio, Junho 2010 11
ARTIGO ORIGINAL / ORIGINAL ARTICLE Characterization of a rat model of moderate CKD
of the animal models of moderate 
CKD, and of a further comparison 
with the human pathophysiology of 
moderate CKD, the research on the 
molecular and cellular mechanisms 
underlying the cardio-renal-anaemia 
syndrome and its therapeutics will 
remain limited.
Since there is a lack of informa-
tion in the literature concerning 
animal (rat) models of moderate 
CKD7,9-12, we intended to perform a 
more complete characterization of 
this model, by assessing hemorheo-
logical, biochemical and cardiovas-
cular profi les in a CKD induced by 
partial (¾) nephrectomy.
MATERIAL AND METHODS
Animals, diets and blood pressure 
measurement
Male Wistar rats (Charles River 
Laboratories Inc., Barcelona, Spain), 
250-300g, were maintained in an air 
conditioned room, subjected to 12-h 
dark/light cycles and given standard 
laboratory rat chow (IPM-R20, Leti-
ca, Barcelona, Spain) and free access 
to tap water. Animal experiments 
were conducted according to the Eu-
ropean Communities Council Direc-
tives on Animal Care.
The rats were divided into 2 
groups (7 rats each): a control group 
and a group with surgical CKD in-
duced by a two-stage (3/4) nephrec-
tomy: fi rstly, about half of the left 
kidney was removed by left fl ank in-
cision and, one week later, the right 
kidney was removed through a right 
lateral fl ank incision. All the animals 
from the two groups have completed 
the 15-week study protocol. Body 
weight (BW) was monitored during 
the experimental period.
Systolic blood pressure (SBP), 
diastolic blood pressure (DBP), mean 
blood pressure (MBP) and heart rate 
(HR) values were obtained using a 
tail-cuff sphygmomanometer LE 
5001 (Letica, Barcelona, Spain) in 
appropriate contention cages. Before 
the measurements, the rats were 
warmed for 10-20 minutes at 25-30ºC 
to make the tail artery pulsations de-
tectable and to achieve the pulse 
level needed. BP and HR values were 
obtained calculating the average of 
8-10 measurements.
Sample collection and preparation
Blood samples: At the beginning 
of the experiments and at 3, 9 and 15 
weeks after the surgical partial neph-
rectomy the rats were subjected to 
intraperitoneal anesthesia with a 2 
mg/kg BW of a 2:1 (v:v) 50 mg/mL 
ketamine (Ketalar®, Parke-Davis, 
Laboratórios Pfeizer, Lda, Seixal, 
Portugal) solution in 2.5% chlorpro-
mazine (Largactil®, Rhône-Poulenc 
Rorer, Laboratórios Vitória, Ama-
dora, Portugal). Blood samples were 
immediately collected by venipunc-
ture from the jugular vein into sy-
ringes without anticoagulant (for se-
rum samples collection) or with the 
appropriate anticoagulant: ethylene-
diaminetetraacetic acid (EDTA), 
heparin or a solution of ACD (acid 
citrate-dextrose). Blood was centri-
fuged (160 g for 10 min. at 20ºC) to 
obtain the platelet rich plasma (PRP), 
which was then centrifuged (730 g 
for 10 min. at 20ºC) to obtain the 
platelet pellet and the platelet poor 
plasma (PPP). In order to maintain a 
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normal volemia, thus ensuring that 
results were not changed by the 
amount of blood collected, some pa-
rameters were analyzed only at the 
fi nal time (15 weeks), namely serum 
oxidative and infl ammatory markers 
and circulating catecholamines and 
serotonin contents.
Body and tissues weights and tro-
phism indexes: At the end of experi-
ments, the rats were sacrifi ced by 
cervical dislocation and the heart, the 
adrenals, the kidneys and the liver 
were immediately removed, placed 
in ice-cold Krebs’ buffer and care-
fully cleaned of adherent fat and con-
nective tissue. The BW, the whole 
heart weight (HW), the left ventricle 
weight (LVW), the adrenals (2: left 
plus right) weight (AW), and the kid-
ney and liver weights were measured 
in all the rats under study in order to 
be used as trophism indexes.
Biochemical assays
Blood lipid: Serum total choles-
terol (Total-c), high-density lipopro-
tein cholesterol (HDL-c), low-densi-
ty lipoprotein cholesterol (LDL-c) 
and triglycerides (TGs) were analy-
sed on a Hitachi 717 analyser (Roche 
Diagnostics Inc., MA, USA) using 
standard laboratorial methods. The 
main relationships between the Total-
c, HDL-c and LDL-c blood concen-
trations were calculated to be used as 
atherogenic and cardiovascular risk 
indexes (LDL-c/HDL-c and Total-c/
HDL-c).
Renal functions and hepatic en-
zymes: Serum creatinine, ureia and 
uric acid concentrations were used as 
renal function indexes and serum as-
partate (AST) and alanine amin-
otransferase (ALT) levels were as-
sessed for hepatic evaluation, through 
automatic validated methods and 
equipments (Hitachi 717 analyser).
Iron metabolism: Serum iron con-
centration was determined using a 
colorimetric method (Iron, Randox 
Laboratories Ltd., North Ireland, 
UK), whereas serum ferritin and 
transferrin were measured by immu-
noturbidimetry (Laboratories Ltd., 
North Ireland, UK).
Hematological data
Several hematological parameters 
were measured in EDTA whole blood 
by using an automatic Coulter Coun-
ter® (Beckman Coulter Inc., USA, 
CA): red blood cell (RBC) count, 
haematocrit, haemoglobin (Hb) con-
centration, hematological indices 
[mean cell volume (MCV), mean cell 
Hb (MCH) and mean cell Hb concen-
tration (MCHC)], red cell distribu-
tion width (RDW), reticulocyte 
count, immature reticulocyte fraction 
(IRF), platelets count, platelets indi-
ces [mean platelet volume (MPV), 
platelet distribution width (PDW) 
and plaquetocrit (PCT)], and total 




cies (TBARs) assay: The blood serum 
was used to determine the products of 
lipid peroxidation, namely malondial-
dehyde (MDA), according to a method 
optimized by Estepa et al. (2001)13.
Ferric reducing antioxidant po-
tential (FRAP) assay: The serum an-
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tioxidant capacity was measured as 
FRAP, according to previously de-
scribed14.
Serum 3-nitrotyrosine (3-NT) as-
say: Serum 3-NT concentration, 
which is an index of peroxynitrite for-
mation, was quantifi ed by using an 
enzymatic immunoassay (HyCult bio-
technology b.v.; Uden, Netherlands).
Infl ammatory markers
Serum levels of interleukin 2 (IL-
2), IL-1β, transforming growth factor 
β1 (TGF-β1) and tumour necrosis 
factor α (TNF-α) were measured by 
ultrasensitive Quantikine® ELISA 
kits (R&D Systems, Minneapolis, 
USA). Serum C-reactive protein 
(CRP) was determined by using an 
ELISA kit from Helica Biosystems, 
Inc. (Fullerton, CA, USA). All assays 
were performed in duplicate.
Catecholamine assay
The contents of the catecholamines 
(CAs) norepinephrine (NE) and epi-
nephrine (E) in the plasma, platelets, 
adrenals and kidney tissue were 
evaluated by high performance li-
quid chromatography with electro-
chemical detection (HPLC-ED), ac-
cording to the procedures and 
chromatographic conditions pre-
vious ly described15.
NE and E contents were measured 
by using known concentrations of 
standards (Sigma Chemical Co., St. 
Louis, MO, U.S.A.) and the internal 
standard dihydroxybenzylamine 
(DHBA), through the peak/area ratio 
technique. Chromatograms were ob-
tained using the appropriate Gilson 
710 software. Concentrations were 
expressed in: ng/ml for plasma and 
platelets, μg/g wet tissue for adrenals 
and ng/g for kidney.
Platelet and plasma serotonergic 
measures
Platelet and plasma 5-hydroxy-
tryptamine (5-HT) and 5-hydroxyin-
doleacetic acid (5-HIAA) contents 
were determined by HPLC-ED, ac-
cording to the preparation/extraction 
procedures and the chromatographic 
conditions previously described [15], 
and calculated using a known con-
centration of the corresponding stan-
dard. Chromatograms were obtained 
using the appropriate Gilson 710 
software. Values were expressed in 
ng/ml.
Kidney histology
The left kidney tissue of the con-
trol rats and the remnant left kidney 
tissue of the CKD animals were im-
mersion-fi xed in 4% buffered para-
formaldehyde (PFA) and processed 
for paraffi n sectioning. Three slices 
from each kidney were embedded. 
Three micrometre thick sections were 
stained with the haematoxylin-eosin 
(H&E). At least 50 glomeruli were 
evaluated per kidney tissue.
Data Analysis
For statistical analysis, we used 
the Statview 4.53 software from Aba-
cus Concepts Inc. (Berkeley, CA, 
USA). Results are presented as means 
± standard error of means (s.e.m.). 
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Comparisons between groups and be-
tween different times of evaluation 
were performed using Factorial ANO-
VA and Fisher’s test. Signifi cance 
was accepted at p less than 0.05.
RESULTS
Biochemical and hematological data
In Tables 1 and 2, we present the 
biochemical and hemorheological 
changes for CKD and control rats, 
before starting experiments and along 
the experimental period (at 3, 9 and 
15 weeks after partial nephrectomy). 
The results were analysed in order to 
study the alterations associated with 
a moderate CKD during 15 weeks of 
follow-up, as compared to the control 
group. In CKD rats, three weeks after 
the partial (3/4) nephrectomy, a statis-
tically signifi cant increase in serum 
urea and creatinine concentrations 
were found. This increase in renal 
function markers remained high 
along the following 12 weeks of the 
experimental procedure (Table 1).
Concerning to hepatic function 
markers, a statistically signifi cant in-
crease was found in CKD rats for 
AST and ALT, particularly for the for-
mer at 9 weeks of the experimental 
period; at the end of experiments (15 
weeks) only AST activity was still 
signifi cantly higher. CKD rats pre-
sented alterations in the lipidic pro-
fi le, namely, a progressively increase 
in Total-c, TGs and HDL-c (table 1). 
Iron status evaluation revealed, in 
CKD rats, a progressively increase in 
ferritin serum levels, which reached 
statistical signifi cance in the last eva-
luation. On the contrary, transferrin 
serum levels were signifi cantly lower 
3 weeks after surgical procedure, and 
remained lower during the following 
12 weeks of follow-up (Table 1).
Concerning to hematological data, 
3 weeks after nephrectomy, the CKD 
animals showed a statistically sig-
nifi cant decrease for RBC count, Hb 
and haematocrit, alongside with a 
signifi cantly increase in RDW and in 
platelet count (table 2). These param-
eters were already similar to those of 
the control at 9 weeks after surgical 
intervention and remained stable un-
til the end of the follow-up period. 
No statistically signifi cant differen-
ces were found for total WBC counts; 
however, neutrophil and eosinophil 
counts increased progressively in 
CKD rats. In this group, basophil 
counts increased 3 weeks after chirur-
gic procedure, and decreased pro-
gressively during the remaining fol-
low-up period, and monocyte counts 
increased only in the last laboratorial 
evaluation (Table 2).
Blood pressures, heart rate and 
body and tissue weights and 
trophism indexes
At the end of the experimental 
protocol (15 weeks), a statistically 
significant increase in SBP, DBP, 
MBP and HR were found in CKD 
rats, together with signifi cant increa-
ses in heart and left ventricle weights, 
without any differences in the tissue 
trophism indexes (Table 3).
Oxidative equilibrium status and 
infl ammatory markers
No statistically signifi cant altera-
tions were found between the two 
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Table 1. Biochemical changes in a rat model of moderate CKD during a follow-up period of 15 weeks
Control 























Creatinine (mg/dL)  0.41 ± 0.02  0.40 ± 0.02  0.83 ± 0.04 aa  0.33 ± 0,01  0.81 ± 0.05 aa  0.45 ± 0.02  0.91 ± 0.06 aa
Urea (mg/dL) 41.00 ± 0.68 39.20 ± 0.60 71.00 ± 2.65 a 34.50 ± 1.34  72.80 ± 2.41 aa  39.00 ± 1.58 67.83 ± 2.82 a
Uric acid (mg/dL)  0.60 ± 0.06  0.52 ± 0.05 0.46 ± 0.04  0.34 ± 0.06 0.40 ± 0.04  0.62 ± 0.16 0.48 ± 0.09
Hepatic Enzymes 
AST (IU/L) 68.25 ± 4.73  64.11 ± 3.42 56.70 ± 3.46 51.37 ± 1.21 72.00 ± 3.97 aa 81.00 ± 8.35  141.40 ± 10.83 aaa
ALT (IU/L) 34.00 ± 2.32  32.70 ± 2.31 29.33 ± 1.73 25.32 ± 1.35  39.60 ± 1.63 aaa 33.67 ± 2.32  36.00 ± 2.67
Lipid Profi le
Total-c (mg/dL) 54.33 ± 1,54  51.51 ± 1.49  71.80 ± 4.34 a 43.87 ± 3.12  84.28 ± 6.,51 aaa 55.40 ± 4.01 111.40 ± 5.22 aaa
HDL-c (mg/dL) 44.83 ± 1.22  41.77 ± 1.21  57.87 ± 2.89 a 34.37 ± 2.69  67.57 ± 4.42 aaa 42.60 ± 2.64  81.00 ± 4.18 aaa
LDL-c (mg/dL) 21.02 ± 0.78  19.31 ± 1.22  12.72 ± 1.10 aa 17.49 ± 1.00  15.81 ± 1.57 16.88 ± 1.09  16.01 ± 0.72
TGs (mg/dL)  131.66 ± 4.98  126.71 ± 8.82  84.20 ± 7.84  111.00 ± 10.28  162.40 ± 35.64 139.00 ± 21.24 207.00 ± 38.25 a
LDL-c/HDL-c  0.47 ± 0.03  0.48 ± 0.04  0.22 ± 0.02 aa  0.53 ± 0.04  0.25 ± 0.05 aaa  0.40 ± 0.05  0.20 ± 0.02 a
Total-c/HDL-c  1.21 ± 0.02  1.24 ± 0.02  1.21 ± 0.02  1.29 ± 0.04  1.24 ± 0.02  1.30 ± 0.04 1.38 ± 0.05
Iron metabolism
Iron (μg/dL) 153.16 ± 12.89 108.91 ± 16.52  145.25 ± 8.74 194.27 ± 5.70  155.28 ± 7.51  154.20 ± 26.92  124.50 ± 11.91
Ferritin (ng/mL)  12.63 ± 1.35  12.02 ± 1.39  17.96 ± 1.12  10.01 ± 1.05  21.32 ± 2.14  12.92 ± 3.68 24.66 ± 5.32 a
Transferrin (mg/dL)  130.33 ± 3.79  130.91 ± 3.64  104.80 ± 2.79 aa 130.00 ± 2.47 106.01 ± 5.79aa  120.00 ± 7.97  81.57 ± 11.02 aaa
AST: aspartate aminotransferase; ALT: alanine aminotransferase; CKD: chronic kidney disease; HDL-c: high density lipoprotein-cholesterol; LDL-c: low 
density lipoprotein-cholesterol; TGs: triglycerides; Total-c: serum total cholesterol. Results are presented as mean ± s.e.m.: a – p< 0.05, aa – p< 0.01 and aaa 
– p< 0.001 vs the control group

























Hb (g/dL) 13.82 ± 0.14 13.52 ± 0.21  11.42 ± 0.22 a 12.90 ± 0.18 13.70 ± 0.22 13.94 ± 0.36 13.44 ± 0.20
Haematocrit (%) 39.50 ± 0.49 38.61 ± 0.50  32.81 ± 0.62 a 36.34 ± 0.52 40.20 ± 0.21 40.92 ± 0.71 39.54 ± 0.57
RBC (x1012/L)  7.32 ± 0.12  7.13 ± 0.11  6.18 ± 0.12 a  6.39 ± 0.08  7.25 ± 0.19  7.44 ± 0.10  6.91 ± 0.14
MCV (fL) 53.95 ± 0.62 54.71 ± 0.53 53.09 ± 0.48 57.04 ± 0.64 55.54 ± 0.72 55.04 ± 1.32 57.27 ± 0.66
MCH (pg) 18.85 ± 0.25 19.23 ± 0.23 18.49 ± 0.17 20.20 ± 0.25 18.96 ± 0.36 18.74 ± 0.61 19.48 ± 0.28
MCHC (g/dL) 34.93 ± 0.19 34.91 ± 0.20 34.84 ± 0.13 35.43 ± 0.15 34.14 ± 0.33 34.04 ± 0.37 34.00 ± 0.30
RDW (%) 13.33 ± 0.43 13.23 ± 0.31  15.27 ± 0.35 a 12.58 ± 0.36 13.00 ± 0.20 14.88 ± 0.39 13.54 ± 0.23
Reticulocytes (x109/L) 389.01 ± 29.10 393.11 ± 22.97 423.09 ± 20.01 379.11 ± 39.95 392.09 ± 34.04 383.98 ± 28.97 326.09 ± 27.02
IRF (%)  0.38 ± 0.02  0.39 ± 0.03  0.41 ± 0.02  0.52 ± 0.07  0.42 ± 0.05  0.38 ± 0.01  0.56 ± 0.09
WBC parameters
WBC (x109/L) 6.87 ± 1.19 6.51 ± 1.02 6.69 ± 0.38 5.14 ± 0.91 6.39 ± 0.29 5.14 ± 0.22 5.53 ± 0.85
Neutrophils (x109/L) 0.08 ± 0.01 0.07 ± 0.01 0.10 ± 0.01 0.05 ± 0.01  0.25 ± 0.17 a 0.07 ± 0.01  0.52 ± 0.31 a
Lymphocytes (x109/L) 5.82 ± 1.04 5.51 ± 0.81 4.38 ± 0.43 4.37 ± 0.79 4.86 ± 0.34 4.32 ± 0.81 4.65 ± 0.74
Basophils (x109/L) 1.15 ± 0.33 1.01 ± 0.22  1.89 ± 0.30 a 0.65 ± 0.15  1.25 ± 0.23 a 0.91 ± 0.52  0.29 ± 0.18 a
Eosinophils(x109/L) 0.012 ± 0.002 0.015 ± 0.003 0.023 ± 0.003 0.015 ± 0.003  0.028 ± 0.004 a 0.023 ± 0.007  0.064 ± 0.032 a
Monocytes (x109/L) 0.007 ± 0.002 0.006 ± 0.002 0.009 ± 0.003 0.005 ± 0.002 0.001 ± 0.001 0.004 ± 0.002  0.018 ± 0.010 a
Platelet parameters
Platelets (x109/L) 980.50 ± 22.79 973.41 ± 22.62 1203.80 ± 47.93 a 943.87 ± 32.60 938.43 ± 49.85 980.40 ± 33.07  943.85 ± 78.49
PCT (%)  0.57 ± 0.02  0.56 ± 0.02  0.66 ± 0.02 a  0.54 ± 0.02  0.51 ± 0.02  0.58 ± 0.02  0.56 ± 0.03
MPV (fL)  5.83 ± 0.17  5.73 ± 0.12  5.53 ± 0.07  5.69 ± 0.07  5.50 ± 0.08  5.90 ± 0.14  5.70 ± 0.11
PDW (%) 16.15 ± 0.21 16.22 ± 0.19 15.99 ± 0.14  16.30 ± 0.24  16.04 ± 0.23 16.68 ± 0.26 16.60 ± 0.22
CKD: chronic kidney disease; Hb: hemoglobin; IRF: immature reticulocyte fraction; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglo-
bin concentration; MCV: mean corpuscular volume; MPV=Mean platelet volume; PCT: plateletocrit; PDW: platelet distribution width; RBC: red blood cell; 
RDW: red deviation weight; WBC: white blood cell. Results are presented as mean ± s.e.m.: a – p< 0.05, aa – p< 0.01 and aaa – p< 0.001 vs the control group
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rats groups for MDA and TAS, but a 
signifi cantly higher serum concentra-
tion of 3-NT was found. Concerning 
the inflammatory profile, we ob-
served no signifi cant differences be-
tween the two groups for CRP, IL-1β, 
IL-2 and TNF-α, excepting for 
TGF-β1 that augmented in CKD rats 
(Table 4).
Catecholamine and serotonin 
measures
Concerning sympathetic activity, 
CKD rats presented a statistically sig-
nifi cant increase in plasma and kidney 
NE, and a decrease in platelet content; 
a signifi cant reduction in platelet and 
adrenals E, and a concomitant incre-
ment in plasma E concentration were 
also observed (Fig. 1). Peripheral se-
rotonergic measures in the CKD rats 
after the 15 weeks of follow-up 
showed a trend to higher values for all 
parameters, when compared to control 
animals, even though a statistically 
signifi cant augment was only found 
for platelet 5-HIAA (Fig. 2).
Kidney morphology
The kidney morphology of the 
CKD rats was distinct from that of 
the controls (Fig. 3). The glomerular 
Table 3. Blood pressures, heart rate and body and tissue weights and trophism indexes in a rat model of mode-





Blood Pressures and Heart Rate 
SBP (mmHg) 114.88 ± 3.08  143.07 ± 4.61 aaa
DBP (mmHg)  99.11 ± 1.76  123.31 ± 12.38 aa
MBP (mmHg) 104.33 ± 1.89  129.64 ± 9.79 aaa
HR (beats/min.) 339.12 ± 6.28  391.89 ± 12.00 aaa
Body and Tissue Weights
BW (Kg)  0.47 ± 0.02  0.46 ± 0.01
HW (g)  1.21 ± 0.03  1.46 ± 0.06 a
LVW (g)  0 .57 ± 0.03  0.72 ± 0.04 a
KW (g)  1.24 ± 0.04 1.94 ± 0.20
LW (g)  15.91 ± 0.58  18.23 ± 0.77
AW (g)  0.09 ± 0.01 0.10 ± 0.01
Tissue Trophism Indexes
HW/BW (g/kg)  2.65 ± 0.07 2.98 ± 0.10
LVW/HW (g/kg)  0.47 ± 0.02 0.50 ± 0.02
LVW/BW (g/kg)  1.05 ± 0.11 1.17 ± 0.14
KW/BW (g/kg)  2.62 ± 0.05 3.96 ± 0.39
LW/BW (g/kg)  33.90 ± 0.10 38.80 ± 2.51
AW/BW (g/kg)  0.18 ± 0.02 0.20 ± 0.02
AW: adrenals weight; BW: body weight; CKD: chronic kidney disease; DBP: diastolic blood pressure; HR: 
heart rate; HW: heart weight; KW: kidney weight; LVW: left ventricle weight; LW: liver weight; MBP: mean 
blood pressure; SBP: systolic blood pressure. Results are presented as mean ± s.e.m.: a – p< 0.05, aa – p< 0.01 
and aaa – p< 0.001 vs the control group
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capillary tufts of the CKD rats were 
hypercellular, with an increment of 
the glomerular volume. The Bowman 
space was also higher (Fig. 3B1). The 
interstitial region was lower due to 
tubular atrophy, together with an ex-
pansion of proximal convoluted tu-
bules (Fig. 3B2).
DISCUSSION
Early detection of CKD and ini-
tiation of treatment should contribute 
to prevent or delay some of these ad-
verse effects16. However, animal 
models of moderate CKD, which 
might be good tools to study the 
pathophysiological mechanisms un-
derlying intermediary stages of renal 
disease and the effi cacy of therapeu-
tics, remain to be fully characterized. 
Our results have confi rmed that the 
surgical partial (3/4) nephrectromy 
produces a moderate, but sustained 
stage of CKD. Indeed, we observed 
a signifi cant (but restrained) increase 
in serum urea and creatinine concen-
trations at 3 weeks after the surgery 
that remained almost constant during 
the following period (still signifi cant-
ly higher than controls).
Furthermore, the results observed 
for RBC and reticulocyte counts, 
were similar to those observed for 
serum urea and creatinine along the 
follow-up period, further strengthens 
that a moderate stage of CKD was 
generated. RBC count was signifi -
cantly lower 3 weeks after nephrec-
tomy, consistent with the develop-
ment of anaemia secondary to renal 
mass reduction; moreover, the num-
ber of reticulocytes, as well as the 
percentage of immature reticulocytes 
did not increase, further supporting a 
failure of the erythropoietic response 
mechanisms, due to insufficient 
erythropoietin production associated 
to the reduction in renal tissue. How-
ever, the anaemia was notoriously 
transitory, as both RBC and reticulo-







MDA (μmol/L)  0.27 ± 0.05  0.34 ± 0.06
TAS (μmol/L)  394.72 ± 51.42  408.03 ± 23.62
MDA/TAS  0.56 ± 0.05  0.73 ± 0.21
3-NT (nmol/L) 15.66 ± 1.40  50.45 ± 3.22 aaa
Infl ammatory Profi le
CRP (μg/mL) 24.78 ± 1.25  25.83 ± 0.66
IL-1β (pg/mL) 26.52 ± 0.94  23.76 ± 0.99
IL-2 (pg/mL) 36.28 ± 8.70  49.34 ± 3.43
TGF-β1 (pg/mL)  358.41 ± 34.52  544.42 ± 50.43 a
TNF-α (pg/mL) 16.34 ± 1.81  15.75 ± 1.96
CKD: chronic kidney disease; CRP: C-reactive protein; IL-1β: interleukin 1β; IL-2: interleukin 2; MDA: ma-
londialdehyde; TAS: total antioxidant status; TGF-β1: transforming growth factor β1; TNF-α: tumour necrosis 
factor α; 3-NT: 3-nitrotyrosine. Results are presented as mean ± s.e.m.: a – p< 0.05, aa – p< 0.01 and aaa – p< 
0.001 vs the control group
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Fig. 1. Norepinephrine and epinephrine contents in plasma, platelets, adrenals and kidneys in a rat model of 
moderate CKD after an experimental period of 15 weeks. E: epinephrine; NE: norepinephrine. Results are pre-
sented as mean ± s.e.m.: a – p< 0.05, aa – p< 0.01 and aaa – p< 0.001 vs the control group. NS: non-signifi cant
Fig. 2. Plasma and platelet 5-HT and 5-HIAA in a rat model of moderate CKD after an experimental period of 15 
weeks. 5-HT: 5-hydroxy-tryptamine; 5-HIAA: 5-hydroxyindoleacetic acid. Results are presented as mean ± s.e.m.: 
NS: non-signifi cant
cyte values returned to normal values 
in the following evaluation points (9 
and 15 weeks of study), suggesting 
that our model is a moderate (but yet 
functional) CKD. This pattern is also 
confi rmed by the low-grade histo-
morphological changes (lesions) 
found in the kidneys of CKD rats. 
There was also a trend to increased 
kidney weight (hypertrophy), consis-
tent with a compensated renal insuf-
fi ciency. Similar hypertrophy was 
obtained in other models of chronic 
renal failure induction, such as the 
5/6 nephrectomized rats9-12.
Iron-restricted erythropoiesis is a 
common clinical condition in patients 
with CKD. Several causes were pro-
posed to underlie this situation, such 
as a functional iron defi ciency, inad-
equate dietary iron intake, blood loss 
during the haemodialysis processes 
or from gastrointestinal tract (bleed-
ing), inadequate intestinal iron ab-
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sorption and inhibition of iron mobi-
lization from macrophages17. In our 
study, CKD rats presented serum iron 
values similar to those of the control 
and no signifi cant changes were ob-
served along the experiments; how-
ever, a trend towards higher values of 
ferritin were observed along the ex-
periments and reached a signifi cantly 
higher value at the end (15 weeks); 
these changes in ferritn were accom-
panied by a signifi cant reduction in 
transferrin (observed at 3 weeks and 
afterwards), suggesting an inhibition 
in iron traffi c, from macrophages to 
erythroid cells, leading to the pro-
gressive increase in iron storage, as 
showed by the progressive increase 
in ferritin, observed throughout the 
experiments. This suggests that our 
moderate model of CKD could also 
be used as a model of functional iron 
Fig. 3. Renal histology of kidneys from control (A) and moderate chronic CKD rats (B): 1 – glomerular region; 
2 – proximal convoluted tubules area (original amplifi cation x10 and x40, respectively for fi gures 1 and 2).
defi ciency. Indeed, a functional iron 
defi ciency has been reported in CKD 
patient under hemodialysis, namely, 
in moderate stages17,18.
Liver metabolism dysfunction 
should plays a role in the lipid profi le 
changes encountered in the CKD 
rats: increased values of total-choles-
terol, HDL-c and TGs, without dif-
ferences on LDL-c content, which 
might be explained, at least in part, 
by the lack in cholesteryl ester trans-
fer protein (CETP), a characteristic 
of the rats19,20. Lipid abnormalities 
are found in CKD humans and the 
prevalence of hyperlipidaemia is 
higher than in the general popula-
tion21,22. However, the risk of cardio-
vascular disease in CKD patients va-
ries depending on the type of lipid 
abnormalities, the cause of renal di-
sease and the degree of reduction in 
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glomerular fi ltration rate (GFR)23. 
Our rat model reproduces the chan-
ges encountered in CKD patients, in 
whom the main features are an in-
creased serum level of both VLDL 
and IDL fractions, leading to hyper-
triglyceridemia and an unchanged or 
slightly increased LDL fraction en-
riched with triacylglycerols that 
might be attributed to the slow ca-
tabolism of the triacylglycerol-rich 
lipoproteins24-26.
Besides the anaemia secondary to 
CKD, patients usually develop car-
diac failure that further aggravates 
renal disease [2, 27, 28]. This triad of 
dysfunctions, already known as car-
dio-renal anaemia syndrome, is re-
sponsible for the serious complica-
tions encountered in those patients. 
Our study intended to clarify the de-
gree of cardio-renal complications 
associated with this model of mode-
rate CKD. Hypertension is a well 
established cause, a common compli-
cation, and an important risk factor 
for progression of the cardiovascular 
complications and the mortality of 
patients with CKD4,5; the pathophy-
siology of this hypertension is multi-
factorial4. Several authors conclude 
that CKD also activates (through the 
renin-angiotensin system participa-
tion) the sympathetic nervous system 
(SNS)1. Our results obtained using an 
animal model seem to be in agree-
ment with the data from humans with 
CKD, despite a direct extrapolation 
from rat studies to humans deserves 
careful interpretation. In any case, an 
increased systolic and diastolic blood 
pressure was obtained, together with 
tachycardia and heart and left ven-
tricle hypertrophy, which should be 
due to additional heart (left ventricle) 
effort to compensate the renal func-
tion deterioration. The kidneys, stra-
tegically positioned, have dense sen-
sory and efferent sympathetic 
innervations, and can be the origin, 
as well as the target of overactivity of 
the SNS, which has been convinc-
ingly shown in CKD animal mo-
dels29. Several studies showed that 
sub-totally nephrectomized rats de-
veloped a rapid increase of BP with-
in a week after renal ablation, while 
totally nephrectomized rats, in which 
afferent sensory signals were re-
moved, did not develop hypertension. 
This suggests that afferent signals 
from the disease kidneys are trans-
mitted to the vasomotor control cen-
tre in the brain, thereby contributing 
to the increased blood pressure1. In 
our model of moderate CKD, plasma 
norepinephrine and epinephrine con-
tents were increased, which might be 
caused by adrenal and platelet re-
lease, due to sympathetic system 
overactivation and platelet hyper-
reactivity, respectively. Moreover, 
plasma 5-HT was also increased, 
which, together with catecholamine 
increment, might infl uence platelet 
and vascular reactivity and, thus, 
contributing to cardiovascular and 
thromboembolic complications, as 
found in CKD patients30-32.
Other factors have been studied to 
clarify the causes of the hypertension 
observed in CKD patients, including 
high levels of endothelin, oxidative 
stress or nitric oxide (NO) reduc-
tion4,33-35. In CKD patients, oxidative 
stress and infl ammation could play a 
crucial role in the pathogenesis of the 
atherosclerosis, malnutrition and 
anaemia. In our model of moderate 
CKD, the redox state seems to be un-
altered (MDA/TAS ratio was un-
changed) which might be due to a 
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proper compensation of ROS forma-
tion by antioxidants. However, there 
was an increased serum 3-NT value, 
which is a marker of peroxynitrite 
generation, and, thus, might hypo-
thetically refl ect an increased super-
oxide formation and, thus, a reduced 
NO availability, since this dangerous 
oxidant is formed by the combination 
of both. In this model, infl ammation 
seem to be yet less relevant, since, 
excepting an increment of TGF-β1, 
all the other markers were unchanged. 
The increment in ferritin, an acute 
phase protein, might also be viewed 
as part of an infl ammatory state. The 
involvement of infl ammation on this 
model of moderate CKD should be 
further confi rmed, namely, by studies 
on the hypertrophic remnant kidney.
In conclusion, our model is con-
sistent with a moderate but sustained 
degree of CKD with a compensated 
anaemia, though presenting a distur-
bance in iron metabolism. Despite 
the reasonable degree of functional-
ity of the remnant kidney, as sug-
gested by the correction of anaemia 
as well as by the kidney hypertrophy, 
several important cardiovascular 
modifi cations were developed. There-
fore, our model presented hyperten-
sion, dyslipidaemia, sympathetic ac-
tivation and oxidative stress. This 
model might be a good tool to study 
the cellular and molecular pathophys-
iological mechanisms underlying 
moderate stages of CKD, as occurs 
in humans, and, even more relevant, 
to evaluate the effi cacy of therapeu-
tics for prevention, treatment or cor-
rection of cardio-renal anaemia syn-
dromes and complications in early 
stages.
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